SBS says Embecta investors may join securities class action over guidance claims
Schall, Brown & Schwartz LLP says investors who bought Embecta Corp. shares during a stated class period may contact the firm about a securities class action.
Schall, Brown & Schwartz LLP said Aug. 10 that investors who bought Embecta Corp. shares during a stated class period may contact the firm about a securities class action tied to the company’s fiscal guidance.
The law firm’s press release says the case concerns Embecta, which trades on Nasdaq under the ticker EMBC, and alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The release says the proposed class period runs from Nov. 25, 2025, through May 4, 2026.
According to the press release, the complaint alleges Embecta gave investors the impression it had a reliable basis for its fiscal guidance for the second quarter of 2026 and for full-year 2026. The complaint also says the company allegedly knew headwinds in certain markets, including the pen needle market, were likely to affect performance against that guidance.
The release says investors suffered damages when the market learned the truth about Embecta, but it does not provide additional case filings or a court ruling.
The firm said investors who purchased EMBC shares during the class period are encouraged to contact it about possible lead plaintiff appointments. It also said lead plaintiff appointment is not required to participate in any recovery. The press release notes that the class has not yet been certified and that absent class members are not represented by an attorney until certification occurs.
The release lists Brian Schall and David Schwartz as contacts at Schall, Brown & Schwartz LLP in Los Angeles. It also provides the firm’s phone number, website and email address.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.